Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression

Modern Pathology

Volumn 21, Issue 7, 2008, Pages 826-836

  Chen, Lei L ^a   Holden, Joseph A ^a   Choi, Haesun ^b   Zhu, Jing ^b   Wu, Elsie F ^b   Jones, Kimberly A ^a   Ward, John H ^a   Andtbacka, Robert H ^a   Randall, R Lor ^a   Scaife, Courtney L ^a   Hunt, Kelly K ^c   Prieto, Victor G ^d   Raymond, Austin K ^d   Zhang, Wei ^d,e   Trent, Jonathan C ^b   Benjamin, Robert S ^b   Frazier, Marsha L ^b,e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

GIST; Homozygous KIT mutation; SNP

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR;

ARTICLE; CANCER RECURRENCE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR BIOPSY; TUMOR GROWTH;

EID: 46049097771     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.46     Document Type: Article

References (49)

1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
2. Koh JS, Trent JC, Chen LL, et al. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol 2004;19:565-574.
3. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
4. Heinrich MC, Corless CL, Deunsing A, et al. PDG FRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
5. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor a gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-667.
6. Miettinen M, Lasota J. Gastrointestinal stromal tumors - review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
7. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology 2006;48:83-96.
8. Holden JA, Willmore-Payne C, Coppola D, et al. High resolution melting amplicon analysis as a method to detect c-Kit and platelet derived growth factor receptor alpha activating mutations in gastrointestinal stromal tumors. Am J Clin Pathol 2007;128:230-238.
9. Fabbro D, Ruetz S, Buchdunger E, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002;93:79-98.
10. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
11. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
12. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-5919.
13. Chen LL, Sabripour M, Andtbacka RHI, et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 2005;7:293-299.
14. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127:294-299.
15. Wakai T, Kanda T, Hirota S, et al. Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation. Br J Cancer 2004;90:2059-2061.
16. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-3337.
17. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-10921.
18. Weinberg RA. Tumor suppressor genes. Science 1991;254:1138-1146.
19. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
20. Raghavan M, Lillington DM, Skoulakis S, et al. Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res 2005;65:375-378.
21. Murthy SK, DiFrancesco LM, Ogilvie RT, et al. Loss of heterozygosity associated with uniparental disomy in breast carcinoma. Mod Pathol 2002;15:1241-1250.
22. Tung WS, Shelvin DW, Kaleem Z, et al. Allelotype of follicular thyroid carcinomas reveals genetic instability consistent with frequent nondisjunctional chromosomal loss. Genes Chromosomes Cancer 1997;19:43-51.
23. Steigen SE, Eide TJ, Wasag B, et al. Mutations in gastrointestinal stromal tumors - a population-based study from Northern Norway. APMIS 2007;115:289-298.
24. Lasota J, vel Dobosz AJ, Wasag B, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 2007;87:1029-1041.
25. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825.
26. Lin W, Yang HH, Lee MP. Allelic variation in gene expression identified through computational analysis of the dbEST database. Genomics 2005;86:518-527.
27. Willmore C, Holden JA, Zhou L, et al. Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Pathol 2004;122:206-216.
28. Lasota J, Dansonka-Mieszkowska A, Stachura T, et al. Gastrointestinal stromal tumors with internal tandem duplications in 3′ end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003;16:1257-1264.
29. Corbacioglu S, Kilic M, Westhoff MA, et al. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin. Blood 2006;108:3504-3513.
30. London CA, Galli SJ, Yuuki T, et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Exp Hematol 1999;27:689-697.
31. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-1918.
32. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11:1605-1609.
33. Kikuchi H, Yamashita K, Kawabata T, et al. Immunohistochemical and genetic features of gastric and metastatic liver gastrointestinal stromal tumors: sequential analyses. Cancer Sci 2006;97:127-132.
34. Simioni P, Scudeller A, Radossi P, et al. 'Pseudo homozygous' activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost 1996;75:422-426.
35. Brugge JM, Simioni P, Bernardi F, et al. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. J Thromb Haemost 2005;3:2695-2702.
36. Kim HJ, Lim S, Park K, et al. Multiple gastrointestinal stromal tumors with a germline c-kit mutation. Pathol Int 2005;55:655-659.
37. O'Riain C, Corless CL, Heinrich MC, et al. Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features. Am J Surg Pathol 2005;29:1680-1683.
38. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-1572.
39. Mol CD, Dougan DR, Schneider TR, et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 2004;279:31655-31663.
40. Chen LL, Prieto VG, Sabripour M, et al. Loss of heterozygosity with acquisition of homozygous KIT-activating mutation promotes gastrointestinal stromal tumor progression [Abstract]. Proc Am Soc Clin Oncol 2006;23:9530.
41. Haigis KM, Dove WF. A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity. Nat Genet 2003;33:33-39.
42. Tischfield JA, Shao C. Somatic recombination redux. Nat Genet 2003;33:5-6.
43. Zhang J, Lindroos A, Ollila S, et al. Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers. Cancer Res 2006;66:659-664.
44. de Nooij-van Dalen AG, van Buuren-van Seggelen VH, Lohman PH, et al. Chromosome loss with concomitant duplication and recombination both contribute most to loss of heterozygosity in vitro. Genes Chromosomes Cancer 1998;21:30-38.
45. Morley AA, Grist SA, Turner DR, et al. Molecular nature of in vivo mutations in human cells at the autosomal HLA-A locus. Cancer Res 1990;50:4584-4587.
46. Shao C, Deng L, Henegariu O, et al. Mitotic recombination produces the majority of recessive fibroblast variants in heterozygous mice. Proc Natl Acad Sci USA 1999;96:9230-9235.
47. Lamb NE, Hassold TJ. Nondisjunction - a view from ringside. N Engl J Med 2004;351:1931-1934.
48. Shi Q, King RW. Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 2005;437:1038-1042.
49. Minissi S, Degrassi F, Tanzarella C, et al. Direct and indirect non-disjunction in the origin of trisomy in cultured human lymphocytes. Mutagenesis 1999;14:557-562.